Clinical Trials Logo

Clinical Trial Details — Status: Active, not recruiting

Administrative data

NCT number NCT00116805
Other study ID # GS-US-174-0103
Secondary ID
Status Active, not recruiting
Phase Phase 3
First received June 30, 2005
Last updated August 21, 2015
Start date June 2005
Est. completion date February 2016

Study information

Verified date August 2015
Source Gilead Sciences
Contact n/a
Is FDA regulated No
Health authority United States: Food and Drug Administration
Study type Interventional

Clinical Trial Summary

This study is designed to evaluate the safety and antiviral activity of tenofovir disoproxil fumarate (TDF, tenofovir DF) compared to adefovir dipivoxil (ADV) for the treatment of HBeAg-positive chronic hepatitis B. Participants will receive either TDF or the approved hepatitis B therapy ADV. After 48 weeks all participants will be switched to open-label TDF.


Description:

Efficacy of TDF versus ADV will be evaluated for histologic improvement, reductions in serum HBV DNA, changes in liver enzymes, and the generation of antibody to the virus. Safety will be assessed by evaluating adverse events, laboratory abnormalities and the development of drug-resistant mutations. After 48 weeks, all participants will receive open-label TDF, and the efficacy and safety of TDF will be monitored for the remainder of the study.


Recruitment information / eligibility

Status Active, not recruiting
Enrollment 266
Est. completion date February 2016
Est. primary completion date May 2007
Accepts healthy volunteers No
Gender Both
Age group 18 Years to 69 Years
Eligibility Inclusion Criteria:

A patient must meet all of the following inclusion criteria to be eligible for participation in this study:

- Chronic hepatitis B virus (HBV) infection, defined as positive serum hepatitis B s-antigen (HBsAg) for more than 6 months

- 18 through 69 years of age, inclusive

- Active hepatitis B e-antigen (HBeAg) positive chronic HBV infection, with all of the following:

- HBeAg positive at screening

- Alanine aminotransferase (ALT) levels > 2 × ULN and = 10 × the upper limit of the normal range (ULN)

- Serum HBV DNA > 1 million copies/mL at screening

- creatinine clearance = 70 mL/min

- hemoglobin = 8 g/dL

- neutrophils = 1,000 /mL

- Knodell necroinflammatory score = 3 and a Knodell fibrosis score < 4; however, up to 96 patients with cirrhosis, ie, a Knodell fibrosis score equal to 4, will be eligible for enrollment

- Negative serum ß-human chorionic gonadotropin (hCG)

- Nucleotide naïve, ie, no prior nucleotide (TDF or ADV) therapy for > 12 weeks

- Nucleoside naïve, ie, no prior nucleoside (any nucleoside) therapy for > 12 weeks

- Willing and able to provide written informed consent

- Liver biopsy performed within 6 months of baseline and has readable biopsy slides or agrees to have a biopsy performed prior to baseline

Exclusion Criteria:

A patient who meets any of the following exclusion criteria is not to be enrolled in this study:

- Pregnant women, women who are breast feeding or who believe they may wish to become pregnant during the course of the study

- Males and females of reproductive potential who are unwilling to use an effective method of contraception during the study; for males, condoms should be used and for females, a barrier contraception method should be used

- Decompensated liver disease defined as conjugated bilirubin > 1.5 x ULN, prothrombin time (PT) > 1.5 x ULN, platelets < 75,000/mL, serum albumin < 3.0 g/dL, or prior history of clinical hepatic decompensation (eg, ascites, jaundice, encephalopathy, variceal hemorrhage)

- Received any nucleoside, nucleotide (TDF or ADV) or interferon (pegylated or not) therapy within 6 months prior to the pre-treatment biopsy

- Evidence of hepatocellular carcinoma (HCC), ie, a-fetoprotein >50 ng/mL

- Coinfection with hepatitis C virus (HCV), human immunodeficiency virus (HIV), or hepatitis delta virus (HDV)

- Significant renal, cardiovascular, pulmonary, or neurological disease

- Received solid organ or bone marrow transplantation

- Is currently receiving therapy with immunomodulators (eg, corticosteroids, etc.), investigational agents, nephrotoxic agents, or agents susceptible of modifying renal excretion

- Has proximal tubulopathy

Study Design

Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment


Intervention

Drug:
TDF
TDF 300 mg tablet administered orally once daily
ADV
ADV 10 mg tablet administered orally once daily
TDF placebo
Placebo to match TDF administered orally once daily
ADV placebo
Placebo to match ADV administered orally once daily
FTC/TDF
Emtricitabine (FTC) 200 mg/TDF 300 mg fixed-dose combination (FDC) tablet administered orally once daily

Locations

Country Name City State
n/a

Sponsors (1)

Lead Sponsor Collaborator
Gilead Sciences

Countries where clinical trial is conducted

United States,  Australia,  Bulgaria,  Canada,  Czech Republic,  France,  Germany,  Greece,  Italy,  Netherlands,  New Zealand,  Poland,  Spain,  Turkey,  United Kingdom, 

References & Publications (6)

Fung S, Gordon SC, Krastev Z, Horban A, Petersen J, Sperl J, Gane E, Jacobson IM, Yee LJ, Dinh P, Martins EB, Flaherty JF, Kitrinos KM, Dusheiko G, Trinh H, Flisiak R, Rustgi VK, Buti M, Marcellin P. Tenofovir disoproxil fumarate in Asian or Pacific Islan — View Citation

Gordon SC, Krastev Z, Horban A, Petersen J, Sperl J, Dinh P, Martins EB, Yee LJ, Flaherty JF, Kitrinos KM, Rustgi VK, Marcellin P. Efficacy of tenofovir disoproxil fumarate at 240 weeks in patients with chronic hepatitis B with high baseline viral load. H — View Citation

Kitrinos KM, Corsa A, Liu Y, Flaherty J, Snow-Lampart A, Marcellin P, Borroto-Esoda K, Miller MD. No detectable resistance to tenofovir disoproxil fumarate after 6 years of therapy in patients with chronic hepatitis B. Hepatology. 2014 Feb;59(2):434-42. — View Citation

Marcellin P, Buti M, Krastev Z, de Man RA, Zeuzem S, Lou L, Gaggar A, Flaherty JF, Massetto B, Lin L, Dinh P, Subramanian GM, McHutchison JG, Flisiak R, Gurel S, Dusheiko GM, Heathcote EJ. Kinetics of hepatitis B surface antigen loss in patients with HBeA — View Citation

Marcellin P, Gane E, Buti M, Afdhal N, Sievert W, Jacobson IM, Washington MK, Germanidis G, Flaherty JF, Aguilar Schall R, Bornstein JD, Kitrinos KM, Subramanian GM, McHutchison JG, Heathcote EJ. Regression of cirrhosis during treatment with tenofovir dis — View Citation

Tsai NC, Marcellin P, Buti M, Washington MK, Lee SS, Chan S, Trinh H, Flaherty JF, Kitrinos KM, Dinh P, Charuworn P, Subramanian GM, Gane E. Viral suppression and cirrhosis regression with tenofovir disoproxil fumarate in Asians with chronic hepatitis B. — View Citation

Outcome

Type Measure Description Time frame Safety issue
Primary Percentage of Participants With HBV DNA < 400 Copies/mL and Histological Improvement (2-point Reduction in Knodell Necroinflammatory Score Without Worsening in Knodell Fibrosis Score) at Week 48 Complete response was a composite endpoint defined as histological response and HBV DNA < 400 copies/mL. Histological response was based on the Knodell numerical scoring of liver biopsy specimens and defined as at least a 2-point reduction in Knodell necroinflammatory score without worsening in Knodell fibrosis score. The Knodell necroinflammatory score is the combined necrosis and inflammation domain scores and ranges from 0 to 14; the Knodell fibrosis domain score ranges from 0 to 4.
A participant was a nonresponder for the primary endpoint if either biopsy (baseline or end-of-treatment) was missing or if there was not an HBV DNA value available at or beyond Week 40.
Baseline; Week 48 No
Secondary Percentage of Participants With HBV DNA < 400 Copies/mL at Week 48 Week 48 No
Secondary Percentage of Participants With HBV DNA < 400 Copies/mL at Week 96 Week 96 No
Secondary Percentage of Participants With HBV DNA < 400 Copies/mL at Weeks 144, 192, 240, 288, 336, and 384 Weeks 144, 192, 240, 288, 336, and 384 No
Secondary Change From Baseline in HBV DNA at Weeks 48, 96, 144, 192, 240, 288, 336, and 384 Baseline; Weeks 48, 96, 144, 192, 240, 288, 336, and 384 No
Secondary Change From Week 48 in HBV DNA at Weeks 96, 144, 192, 240, 288, 336, and 384 Week 48; Weeks 96, 144, 192, 240, 288, 336, and 384 No
Secondary Percentage of Participants With Histological Response at Week 48 Histological response was based on the Knodell numerical scoring of liver biopsy specimens and defined as at least a 2-point reduction in Knodell necroinflammatory score without worsening in Knodell fibrosis score. The Knodell necroinflammatory score is the combined necrosis and inflammation domain scores and ranges from 0 to 14; the Knodell fibrosis domain score ranges from 0 to 4. Baseline; Week 48 No
Secondary Percentage of Participants With Histological Response at Week 240 Histological response was based on the Knodell numerical scoring of liver biopsy specimens and defined as at least a 2-point reduction in Knodell necroinflammatory score without worsening in Knodell fibrosis score. The Knodell necroinflammatory score is the combined necrosis and inflammation domain scores and ranges from 0 to 14; the Knodell fibrosis domain score ranges from 0 to 4. Baseline; Week 240 No
Secondary Change From Baseline in Knodell and Ishak Necroinflammatory Scores at Week 48 The Knodell necroinflammatory score is the combined score for necrosis and inflammation domains of the Knodell scoring system, and ranges from 0 (best) to 14 (worst). The Ishak score measures the degree of liver fibrosis (scarring) caused by chronic necroinflammation (inflammation leading to cell death) and ranges from 0 (best) to 6 (worst). Baseline; Week 48 No
Secondary Change From Baseline in Knodell and Ishak Necroinflammatory Scores at Week 240 The Knodell necroinflammatory score is the combined score for necrosis and inflammation domains of the Knodell scoring system, and ranges from 0 (best) to 14 (worst). The Ishak score measures the degree of liver fibrosis (scarring) caused by chronic necroinflammation (inflammation leading to cell death) and ranges from 0 (best) to 6 (worst). Baseline; Week 240 No
Secondary Ranked Assessment of Necroinflammation and Fibrosis at Week 48 Participants were ranked as having improvement, no change, worsening, or missing data (compared to Baseline) based on the Knodell scoring system, and results are presented as the percentage of participants in each category. The Knodell necroinflammatory score is the combined score for necrosis and inflammation domains of the Knodell scoring system, which ranges from 0 (best) to 14 (worst). The Knodell fibrosis domain score ranges from 0 (best) to 4 (worst). A decrease of 1 point or more indicated improvement, and an increase of 1 point or more indicated worsening. Baseline; Week 48 No
Secondary Ranked Assessment of Necroinflammation and Fibrosis at Week 240 Participants were ranked as having improvement, no change, worsening, or missing data (compared to Baseline) based on the Knodell scoring system, and results are presented as the percentage of participants in each category. The Knodell necroinflammatory score is the combined score for necrosis and inflammation domains of the Knodell scoring system, which ranges from 0 (best) to 14 (worst). The Knodell fibrosis domain score ranges from 0 (best) to 4 (worst). A decrease of 1 point or more indicated improvement, and an increase of 1 point or more indicated worsening. Baseline; Week 240 No
Secondary Percentage of Participants With Alanine Aminotransferase (ALT) Normalization at Week 48 ALT normalization was defined as ALT > upper limit of normal (ULN) at baseline and within the normal range at the end of blinded treatment. The ULN was 43 U/L for males and 34 U/L for females aged 18 to < 69, and 35 U/L for males and 32 U/L for females aged = 69. Baseline; Week 48 No
Secondary Percentage of Participants With ALT Normalization at Week 96 ALT normalization was defined as ALT > ULN at baseline and within the normal range at Week 96. The ULN was 43 U/L for males and 34 U/L for females aged 18 to < 69, and 35 U/L for males and 32 U/L for females aged = 69. Baseline; Week 96 No
Secondary Percentage of Participants With ALT Normalization at Weeks 144, 192, 240, 288, 336, and 384 ALT normalization was defined as ALT > ULN at baseline and within the normal range at the subsequent time point. The ULN was 43 U/L for males and 34 U/L for females aged 18 to < 69, and 35 U/L for males and 32 U/L for females aged = 69. Baseline; Weeks 144, 192, 240, 288, 336, and 384 No
Secondary Change From Baseline in ALT at Weeks 48, 96, 144, 192, 240, 288, 336, and 384 Baseline; Weeks 48, 96, 144, 192, 240, 288, 336, and 384 No
Secondary Change From Week 48 in ALT at Weeks 96, 144, 192, 240, 288, 336, and 384 Week 48; Weeks 96, 144, 192, 240, 288, 336, and 384 No
Secondary Percentage of Participants With Hepatitis B e Antigen (HBeAg) Loss/Seroconversion at Week 48 HBeAg loss was defined as HBeAg positive at baseline and HBeAg negative at Week 48. Seroconversion to anti-HBe was defined as change of detectable antibody to HBeAg from negative at baseline to positive at Week 48. Baseline; Week 48 No
Secondary Percentage of Participants With HBeAg Loss or Seroconversion to Anti-HBe at Week 96 HBeAg loss was defined as HBeAg positive at baseline and HBeAg negative at Week 96. Seroconversion to anti-HBe was defined as change of detectable antibody to HBeAg from negative at baseline to positive at Week 96. Baseline to Week 96 No
Secondary Percentage of Participants With Hepatitis B S-Antigen (HBsAg) Loss or Seroconversion at Week 48 HBsAg loss was defined as HBsAg positive at baseline and HBsAg negative at Week 48. Seroconversion to anti-HBs was defined as change of detectable antibody to HBsAg from negative at baseline to positive at Week 48. Week 48 No
Secondary Percentage of Participants With HBsAg Loss or Seroconversion to Anti-HBs at Week 96 HBsAg loss was defined as HBsAg positive at baseline and HBsAg negative at the subsequent time point. Seroconversion to anti-HBs was defined as change of detectable antibody to HBsAg from negative at baseline to positive at the subsequent time point. Baseline; Weeks 96, 144, 192, 240, 288, 336, and 384 No
Secondary Percentage of Participants With HBsAg Loss or Seroconversion to Anti-HBs at Weeks 144, 192, 240, 288, 336, and 384 HBsAg loss was defined as HBsAg positive at baseline and HBsAg negative at the subsequent time point. Seroconversion to anti-HBs was defined as change of detectable antibody to HBsAg from negative at baseline to positive at the subsequent time point. Baseline; Weeks 144, 192, 240, 288, 336, and 384 No
Secondary Number of Participants With HBV Genotypic Changes From Baseline at Week 48 (Resistance Surveillance) Of the total number analyzed, participants evaluated for resistance included those with HBV DNA = 400 copies/mL, those with viral breakthrough, and those who discontinued after Week 24 with HBV DNA = 400 copies/mL. Baseline; Week 48 No
Secondary Number of Participants With HBV Genotypic Changes From Baseline at Week 96 (Resistance Surveillance) Of the total number analyzed, participants evaluated for resistance included those with HBV DNA = 400 copies/mL at Week 96 on TDF monotherapy, those with viral breakthrough, those who discontinued after Week 48 with HBV DNA = 400 copies/mL, and those who added emtricitabine to the open-label TDF regimen and had HBV DNA = 400 copies/mL at the time of the addition. Baseline; Weeks 49 to 95 No
Secondary Number of Participants With HBV Genotypic Changes From Baseline at Week 144 (Resistance Surveillance) Of the total number analyzed, participants evaluated for resistance included those with HBV DNA = 400 copies/mL at Week 144 on TDF monotherapy, those with viral breakthrough, those who discontinued after Week 96 with HBV DNA = 400 copies/mL, and those who added emtricitabine to the open-label TDF regimen after Week 96 and had HBV DNA = 400 copies/mL at the time of the addition. Baseline; Weeks 97 to 144 No
Secondary Number of Participants With HBV Genotypic Changes From Baseline at Week 192 (Resistance Surveillance) Of the total number analyzed, participants evaluated for resistance included those with HBV DNA = 400 copies/mL at Week 192 on TDF monotherapy, those with viral breakthrough, those who discontinued after Week 144 with HBV DNA = 400 copies/mL, and those who added emtricitabine to the open-label TDF regimen after Week 144 and had HBV DNA = 400 copies/mL at the time of the addition. Baseline; Weeks 145 to 192 No
Secondary Number of Participants With HBV Genotypic Changes From Baseline at Week 240 (Resistance Surveillance) Of the total number analyzed, participants evaluated for resistance included those with HBV DNA = 400 copies/mL at Week 240 on TDF monotherapy, those with viral breakthrough, those who discontinued after Week 192 with HBV DNA = 400 copies/mL, and those who added emtricitabine to the open-label TDF regimen after Week 192 and had HBV DNA = 400 copies/mL at the time of the addition. Baseline; Weeks 193 to 240 No
Secondary Number of Participants With HBV Genotypic Changes From Baseline at Week 288 (Resistance Surveillance) Of the total number analyzed, participants evaluated for resistance included those with HBV DNA = 400 copies/mL at Week 288 on TDF monotherapy, those with viral breakthrough, those who discontinued after Week 240 with HBV DNA = 400 copies/mL, and those who added emtricitabine to the open-label TDF regimen after Week 240 and had HBV DNA = 400 copies/mL at the time of the addition. Baseline; Weeks 241 to 288 No
Secondary Number of Participants With HBV Genotypic Changes From Baseline at Week 336 (Resistance Surveillance) Of the total number analyzed, participants evaluated for resistance included those with HBV DNA = 400 copies/mL at Week 336 on TDF monotherapy, those with viral breakthrough, those who discontinued after Week 288 with HBV DNA = 400 copies/mL, and those who added emtricitabine to the open-label TDF regimen after Week 288 and had HBV DNA = 400 copies/mL at the time of the addition. Baseline; Weeks 289 to 336 No
Secondary Number of Participants With HBV Genotypic Changes From Baseline at Week 384 (Resistance Surveillance) Of the total number analyzed, participants evaluated for resistance included those with HBV DNA = 400 copies/mL at Week 384 on TDF monotherapy, those with viral breakthrough, those who discontinued after Week 336 with HBV DNA = 400 copies/mL, and those who added emtricitabine to the open-label TDF regimen after Week 336 and had HBV DNA = 400 copies/mL at the time of the addition. Baseline; Weeks 337 to 384 No
See also
  Status Clinical Trial Phase
Recruiting NCT04496882 - Chronic Hepatitis b Patients Switch to tAf After Discontinuation of Nucleoside Analogue Phase 4
Completed NCT04083716 - A Study to Assess the Relative Bioavailability and Food Effect of ABI-H2158 in Healthy Adults Phase 1
Not yet recruiting NCT03038802 - A Randomised Controlled Phase 1 Study of Vaccine Therapy for Control or Cure of Chronic Hepatitis B Virus Infection Phase 1/Phase 2
Completed NCT05310487 - Phase 1 Study of 162, a Novel Neutralizing Antibody Targeting Hepatitis B Surface Antigen, in Healthy Adult Subjects Phase 1
Recruiting NCT06070051 - Dose-Escalation Prime/Boost Therapeutic Vaccination Study Of 2 Chimp Adenoviral Vectors in Adults With Chronic HBV On Nucleos(t)Ide Therapy Phase 1
Terminated NCT05001022 - A Study of ALG-020572 Drug to Evaluate Safety, Tolerability, Pharmacokinetics and Pharmacodynamics After Single Doses in Healthy Volunteers and Multiple Doses in CHB Subjects Phase 1
Recruiting NCT04139850 - The Establishment of Korean Hepatitis B Patients Cohort
Recruiting NCT05343481 - Efficacy of VTP-300 in Chronic Hepatitis B Infection Phase 2
Not yet recruiting NCT05490836 - Functional Cure Rate of Peg-IFNα-2b Combined With TAF in HBeAg Negative CHB Patients N/A
Recruiting NCT04543565 - Pradefovir Treatment for the Patients With Chronic Hepatitis B Virus Infections: a Phase3 Study Phase 3
Active, not recruiting NCT02894918 - A Study to Evaluate Addition of Peginterferon Alfa-2a to Chronic Hepatitis B (CHB) Patients Treated With NAs Phase 4
Not yet recruiting NCT02793791 - Prophylactic Treatment of Hepatic Dysplastic Nodules in HBsAg Positive Patients N/A
Recruiting NCT02287857 - Efficacy and Safety of Domestic Tenofovir Tablets in Chinese Patients With Chronic Hepatitis B N/A
Recruiting NCT01965418 - A Clinical Evaluation on Traditional Chinese Medicine Diagnosis and Treatment Program Blocking and Reversing Hepatitis B-related Liver Fibrosis - a Randomized, Controlled, Double-blind, Multi-center Clinical Trial Phase 4
Recruiting NCT01491295 - Switch to Tenofovir Versus Continue Lamivudine/Adefovir Treatment in Lamivudine-resistance Chronic Hepatitis B Patients Phase 4
Terminated NCT01872988 - Tenofovir Antiviral Therapy Following Transarterial Chemoembolization for HBV Related Hepatocellular Carcinoma Phase 3
Recruiting NCT01487876 - Efficacy and Safety of Dual-plasmid Hepatitis B Virus DNA Vaccine in Chronic Hepatitis B Patients Phase 2
Completed NCT01531166 - A Cohort Study in Korean Patients With Chronic Hepatitis B (CHB) Receiving Pegylated Interferon N/A
Not yet recruiting NCT01436539 - Study of Effects and Safety Between Adefovir Dipivoxil Plus Polyene Phosphatidylcholine Versus Adefovir Dipivoxil Alone in Chronic Hepatitis B Patients Phase 4
Recruiting NCT01360879 - Assessment of Liver FIBROsis by Real-time Tissue ELASTography in Chronic Liver Disease N/A